

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/517,869
Sheet	1	of	1	Filing Date	October 12, 2005
				First Named Inventor	Anders Lehmann
				Art Unit	1614
				Examiner Name	Lewis, Amy A. Spivack
				Attorney Docket Number	1103326-0946

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
					T ⁶

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/P.S./		HORNBY ET AL., "Receptors and Transmission in the Brain-Gut Axis II. Excitatory amino acid receptors in the brain-gut axis", The Am. J. Physiological Society, 280: G1055-G1060, 2001.			
/P.S./		LEHMANN ET AL., "Effects of antagonism of NMDA receptors on transient lower esophageal sphincter relaxations in the dog", European J. of Pharm. 431:253-258, 2001.			
/P.S./		O'LEARY ET AL., "Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism", British J. of Pharm. 131:1429-1437, 2000.			
/P.S./		LIU ET AL., "Agonist-and Reflex-Evoked Internalization of Metabotropic Glutamate Receptor 5 in Enteric Neurons", The J. of Neuroscience, 20(9):3200-3205, May 1, 2000.			
/P.S./		BLACKSHAW ET AL., "Gastrointestinal pharmacology.-new therapeutic vistas", Current Opinion in Pharm. 1:561-562, 2001.			
/P.S./		KIRCHGESSNER, A., "Glutamate in the enteric nervous system", Current Opinion in Pharm. 1:591-596, 2001			
/P.S./		J. T. GREENAMYRE ET AL., "Anatomy and physiology of glutamate in the CNS", Neurology 44 (Suppl. 8), Nov., S7-S13, 1994.			
/P.S./		D. P. HIRSCH ET AL., "Involvement of Glutamate to Transient Lower Esophageal Sphincter Relaxations in Man", Gastroenterology 120, A-630 (3197), 2001.			
/P.S./		J. A. SAUGSTAD ET AL., "L-2-amino-3-phosphonopropionic acid competitively antagonizes metabotropic glutamate receptors 1 α and 5 in <i>Xenopus</i> oocytes", Euro. J. of Pharm. 289:395-397, 1995.			
/P.S./		A. E. KINGSTON ET AL., "Pharmacological Analysis of 4-Carboxyphenylglycine Derivatives: Comparison of Effects on mGluR1 α and mGluR5 α Subtypes", Neuropharm. Vol. 34, 8:887-894, 1995.			
Opposition against EP 1 515 525 B1 filed by Addex Pharma S.A.					
Opposition against EP 1 515 525 B1 filed by Novartis AG					
Examiner Signature	/Phyllis Spivack/		Date Considered	08/11/2009	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.